Literature DB >> 19287931

[Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases].

Licia Maria Henrique da Mota1, Ana Cristina Vanderley Oliveira, Rodrigo Aires Corrêa Lima, Leopoldo Luiz dos Santos-Neto, Pedro Luiz Tauil.   

Abstract

Yellow fever is endemic in some countries. The anti-yellow fever vaccine is the only effective means of protection but is contraindicated for immunocompromised patients. The aim of this paper was to report on a case series of rheumatological patients who were using immunosuppressors and were vaccinated against this disease. This was a retrospective study by means of a questionnaire applied to these patients, who were vaccinated 60 days before the investigation. Seventy patients of mean age 46 years were evaluated. Most of them were female (90%). There were cases of rheumatoid arthritis (54), systemic lupus erythematosus (11), spondyloarthropathy (5) and systemic sclerosis (2). The therapeutic schemes included methotrexate (42), corticosteroids (22), sulfasalazine (26), leflunomide (18), cyclophosphamide (3) and immunobiological agents (9). Sixteen patients (22.5%) reported some minor adverse effect. Among the eight patients using immunobiological agents, only one presented a mild adverse effect. Among these patients using immunosuppressors, adverse reactions were no more frequent than among immunocompetent individuals. This is the first study on this topic.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19287931     DOI: 10.1590/s0037-86822009000100006

Source DB:  PubMed          Journal:  Rev Soc Bras Med Trop        ISSN: 0037-8682            Impact factor:   1.581


  10 in total

1.  Mapping the risk of yellow Fever infection.

Authors:  David R Hill
Journal:  Curr Infect Dis Rep       Date:  2012-06       Impact factor: 3.725

Review 2.  The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review.

Authors:  Roger E Thomas; Diane L Lorenzetti; Wendy Spragins; Dave Jackson; Tyler Williamson
Journal:  Am J Trop Med Hyg       Date:  2012-02       Impact factor: 2.345

Review 3.  [Vaccination prior to travelling for patients with rheumatic diseases].

Authors:  B Ehrenstein
Journal:  Z Rheumatol       Date:  2011-06       Impact factor: 1.372

Review 4.  A Systematic Review and a Meta-Analysis of the Yellow Fever Vaccine in the Elderly Population.

Authors:  Ariane de Jesus Lopes de Abreu; João Roberto Cavalcante; Letícia Wigg de Araújo Lagos; Rosângela Caetano; José Ueleres Braga
Journal:  Vaccines (Basel)       Date:  2022-04-30

5.  [Vaccination in adult patients with chronic inflammatory rheumatic diseases].

Authors:  S Goldacker; A M Gause; K Warnatz
Journal:  Z Rheumatol       Date:  2013-09       Impact factor: 1.372

Review 6.  Occurrence of Autoimmune Diseases Related to the Vaccine against Yellow Fever.

Authors:  Ana Cristina Vanderley Oliveira; Licia Maria Henrique da Mota; Leopoldo Luiz Dos Santos-Neto; Jozélio Freire De Carvalho; Iramaya Rodrigues Caldas; Olindo Assis Martins Filho; Pedro Luis Tauil
Journal:  Autoimmune Dis       Date:  2014-10-22

Review 7.  Yellow fever vaccine and risk of developing serious adverse events: a systematic review.

Authors:  Ruben Porudominsky; Eduardo H Gotuzzo
Journal:  Rev Panam Salud Publica       Date:  2018-06-05

Review 8.  Vaccines, adjuvants and autoimmunity.

Authors:  Luísa Eça Guimarães; Britain Baker; Carlo Perricone; Yehuda Shoenfeld
Journal:  Pharmacol Res       Date:  2015-08-12       Impact factor: 7.658

9.  Yellow fever vaccination in Brazil: Short-term safety and immunogenicity in juvenile autoimmune rheumatic diseases.

Authors:  Nádia Emi Aikawa; Verena Andrade Balbi; Eduardo Ferreira Borba; Adriana Coracini Tonacio; Adriana Maluf Elias Sallum; Lucia Maria Arruda Campos; Kátia Tomie Kozu; Margarete Borges Vendramini; Nicole Fontoura; Adriana de Souza Azevedo; Waleska Dias Schwarcz; Ana Marli Christovam Sartori; Leila Antonangelo; Clovis Artur Silva; Eloisa Bonfá
Journal:  Vaccine X       Date:  2021-12-10

10.  Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.

Authors:  Valéria Valim; Ketty Lysie Libardi Lira Machado; Samira Tatiyama Miyamoto; Arthur Dalmaso Pinto; Priscila Costa Martins Rocha; Erica Vieira Serrano; Valquiria Garcia Dinis; Sônia Alves Gouvêa; João Gabriel Fragoso Dias; Ana Carolina Campi-Azevedo; Andréa Teixeira-Carvalho; Vanessa Peruhype-Magalhães; Ismael Artur da Costa-Rocha; Sheila Maria Barbosa de Lima; Emily Hime Miranda; Gisela Freitas Trindade; Maria de Lourdes de Sousa Maia; Maria Bernadete Renoldi de Oliveira Gavi; Lidia Balarini da Silva; Ruben Horst Duque; Ana Paula Espíndula Gianordoli; Thays Zanon Casagrande; Karine Gadioli Oliveira; Bruna Costa da Mata Moura; Fernanda Nicole-Batista; Luiza Correa Rodrigues; Thalles Brandão Clemente; Enan Sales Magalhães; Maria de Fatima Bissoli; Maria da Penha Gomes Gouvea; Lauro Ferreira da Silva Pinto-Neto; Carolina Zorzanelli Costa; Raquel Altoé Giovelli; Leticia Resende Brandão; Elizandra Tomazela Laurenti Polito; Ingrid de Oliveira Koehlert; Brunela Passos Borjaille; Daniela Bergamim Pereira; Laiza Hombre Dias; Daniela Linhares Merlo; Luiz Fellipe Favoreto Genelhu; Flavia Zon Pretti; Maryella Dos Santos Giacomin; Ana Paula Neves Burian; Francieli Fontana Sutile Tardetti Fantinato; Gecilmara Salviato Pileggi; Lícia Maria Henrique da Mota; Olindo Assis Martins-Filho
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.